Actively Recruiting
Study of How CD19 CAR-T Cells Persist Over Time in Children and Young Adults with Acute Lymphoblastic Leukemia
Led by University College, London · Updated on 2026-08-07
50
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying pediatric and young adult patients with acute lymphoblastic leukemia ALL who have relapsed or refractory disease and are treated with CD19 chimeric antigen receptor T-cells CAR-T cells. This observational study aims to understand how CAR-T cells persist in the body over time and the factors that may cause their loss. Participants include children and young adults up to age 25 who are scheduled to receive the approved CD19-targeted CAR-T cell therapy called Tisagenlecleucel. The study does not involve additional treatments but observes patients receiving this licensed therapy. The research tracks changes in CAR-T cell levels following treatment. During the study, researchers will monitor how long CAR-T cells remain in circulation, with follow-up continuing until one year after the last patient receives treatment. Participants will undergo evaluations as part of their routine care, and data will be collected to assess CAR-T cell persistence. The study is sponsored by University College, London, and will continue through July 2027.
CONDITIONS
Brief Title
Determining the Mechanisms of Loss of CAR T Cell Persistence
Research Team
C
CARPERS Trial Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
